Back to Newsroom

International Stem Cell Corporation to Conduct Parkinson’s Disease Clinical Study in Australia

CARLSBAD, CA–(Marketwired – January 29, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that the company has completed the required preclinical studies and plans to begin the phase 1/2a clinical study of the company’s cell therapy for the treatment of Parkinson’s disease in Australia within the next few months.

Click here to read more